| 23.53 1.01 (4.48%) | 06-12 13:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.29 | 1-year : | 40.62 |
| Resists | First : | 28.5 | Second : | 34.77 |
| Pivot price | 21.34  |
|||
| Supports | First : | 18.35 | Second : | 15.26 |
| MAs | MA(5) : | 21.51 |
MA(20) : | 21.42  |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.6 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 52.1 |
D(3) : | 41.2 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 39.54 | Low : | 14.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MRNX ] has closed below upper band by 8.3%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 22.69 - 22.79 | 22.79 - 22.9 |
| Low: | 19.65 - 19.76 | 19.76 - 19.87 |
| Close: | 22.32 - 22.51 | 22.51 - 22.69 |
The MRNX fund is designed to generate returns by taking a leveraged, bullish stance on the daily share price movements of Moderna, Inc. (MRNA). It achieves this primarily through the use of swap agreements and short-term listed call options. Its objective is to deliver a daily return equivalent to 200% (twice) the daily percentage change in MRNA's stock price, which it maintains through daily rebalancing. However, holding the fund for periods exceeding a single day may lead to actual returns that deviate significantly from this 2x daily target, influenced by factors like market volatility, compounding, and rebalancing impacts. For collateral supporting its derivative contracts, MRNX may also invest in stable assets such as U.S. government securities, money market funds, short-term bond exchange-traded funds (ETFs), and investment-grade corporate debt.
Wed, 27 May 2026
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. - The National Law Review
Sun, 15 Feb 2026
What are the Major Headwinds and Tailwinds Shaping the Biotech Sector in 2026 - Kavout
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management - Leveraged
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|